Welcome to: Rimonabant Information Source (rimonabant in)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

20mg Acomplia diet pill is the usual dose to be taken with a glass of water. Crushing or chewing Acomplia diet tablet, the chemical composition and increase the risk of unwanted side effects. Not more than indulge in drug Acomplia as potentially harmful to your health. Strictly to your doctors? ?¢ recipe for effective weight loss. The mechanism of Acomplia diet pills work mainly of hampering functioning of the CB-1 receptors. These receptors are responsible for the intake of food in the body. If the CB-1 receptors are blocked you usually eat less than your normal appetite. This activity in turn sources effective weight loss.

Rimonabant Pricelist

Please wait while we load the price list
Try not to miss any dose, but if happens so; never try to compensate it by overdosing. Overdosing Rimonabant can be harmful for your health. As in case of other prescription medications, Rimonabant can also cause some side effects. The side effects related with Rimonabant are rare, mild and temporary. Dizziness, nausea, stomach disorder and muscular cramps are the side effects of Rimonabant weight loss pill. The side-effects are short lived and disappear after the use of medication for a few days. However, if symptoms of side effects persist for long, consult you doctor immediately. Rimonabant has high efficacy, which is around 88% percent. This means 9 out of every 10 Rimonabant users have reduced weight.

Among the completers, the difference was 6. 0 kg vs. 1. 9 kg. Similarly, waist circumference in the 20-mg rimonabant group was reduced by 5. 2 cm, compared with 1. 9 cm in the placebo group in the initial cohort; the reductions were 6. 0 cm vs. 2. 4 cm among the completers. More modest results were seen with 5-mg rimonabant, Dr. Scheen noted. Among the completers, 55. 9% in the 20-mg group lost 5% or more of their initial body weight, compared with 19. 5% of the placebo group (49. 4% vs. 14. 5% in the intent-to-treat analysis), whereas 21. 4% and 3. 0% of the completers, respectively, and 16. 4% and 2. 0% of the entire initial group lost 10% or more of their initial body weight. These results are similar to those seen in nondiabetics in the other RIO trials, "which is remarkable, taking into account the well-known difficulty of diabetics to lose weight," he said.